Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 receptor agonists have transformed weight loss treatment, with clinical trials showing average weight reductions of 15-22% over 68 weeks. Tirzepatide and semaglutide stand out as the most studied compounds in this class, yet they function through distinct mechanisms that produce different metabolic outcomes. Choosing between them requires understanding your individual peptide pathways and metabolic needs.

How Tirzepatide and Semaglutide Work in Your Body

Semaglutide activates the glucagon-like peptide-1 receptor, which signals your brain to reduce hunger and increase feelings of fullness. This single-pathway approach helps regulate blood sugar, slow gastric emptying, and decrease overall calorie intake. The medication has been studied extensively in the SUSTAIN trials, demonstrating consistent weight loss across diverse patient populations.

Tirzepatide functions as a dual agonist, activating both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor simultaneously. This two-pathway mechanism appears to produce greater weight loss than semaglutide alone in head-to-head comparisons, with the SURMOUNT trials showing up to 22.5% weight reduction. The dual action also enhances insulin secretion and may offer additional metabolic benefits for individuals with insulin resistance.

Clinical Evidence: Weight Loss Results You Can Expect

Semaglutide delivered average weight losses of 15% in the SUSTAIN-12 trial over 40 weeks, with consistent results across age groups and BMI categories. Patients typically experience gradual weight reduction over 12-16 weeks as their dose escalates, and results continue improving through months 4-6 of treatment. The medication's safety profile has been established across more than 40,000 patient-years of exposure in clinical trials.

Tirzepatide demonstrated superior weight loss outcomes in direct comparison studies, with SURMOUNT-1 showing 22.5% average weight reduction after 68 weeks of treatment at the highest dose. Notably, tirzepatide appears to produce measurable weight loss in both individuals with and without type 2 diabetes, suggesting broader metabolic effectiveness. Patients on tirzepatide also report improvements in cardiovascular risk markers, including blood pressure and cholesterol levels, beyond what semaglutide alone typically achieves.

Choosing Your Medication: Semaglutide Injection vs. Tirzepatide

The choice between these medications depends on your metabolic profile, weight loss goals, and how your body responds to single versus dual pathway activation. Individuals with mild insulin resistance or those seeking a gentler initial approach often respond well to semaglutide, which can be started at lower doses and titrated gradually. Semaglutide injection through PlexusDx starts at $149/month, making it an accessible entry point into GLP-1 therapy.

Patients with moderate to severe insulin resistance, significant weight loss needs, or those who have plateaued on other therapies frequently benefit from tirzepatide's dual mechanism. The medication's ability to address both hunger signaling and glucose metabolism simultaneously makes it particularly effective for individuals with metabolic syndrome. PlexusDx offers compounded tirzepatide injection starting at $249/month, with consistent pricing across all dose levels—your dose may need to go up, but your price won't.

PlexusDx's Precision Peptide Genetic Test can identify your genetic predispositions across 14 metabolic pathways, including variants in the GLP1R, GIPR, FTO, and MC4R genes. This testing reveals whether your genetic profile suggests greater responsiveness to single-pathway GLP-1 activation or dual-pathway therapy, helping guide the most effective medication choice for your body.

Accessing Compounded Tirzepatide and Semaglutide at PlexusDx

PlexusDx compounds both medications through licensed 503A compounding pharmacies, ensuring pharmaceutical-grade quality without requiring insurance or membership fees. All 50 states are served, and both semaglutide and tirzepatide are HSA/FSA eligible, reducing your out-of-pocket costs. The straightforward flat-fee pricing model eliminates surprise expenses as your healthcare provider adjusts your dose upward during treatment.

Beyond injectable options, PlexusDx offers oral semaglutide starting at $249/month and oral tirzepatide starting at $279/month for patients who prefer tablets over injections. The dual-compound GLP-Squared injection, which combines both semaglutide and tirzepatide, is available for patients seeking a novel approach to maximizing peptide pathway activation. After one month of treatment, the optional Precision Peptide Genetic Test ($99 add-on) provides personalized insights into your 150+ genetic metabolic markers.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is tirzepatide more effective than semaglutide for weight loss?

Clinical trials show tirzepatide typically produces greater weight loss than semaglutide—up to 22.5% compared to 15% in comparable timeframes. However, effectiveness varies by individual metabolic profile, genetics, and how your body responds to single versus dual pathway activation. PlexusDx's Precision Peptide Genetic Test can help predict which mechanism may work best for your specific peptide pathways.

How long does it take to see weight loss results?

Most patients notice initial appetite suppression within 2-4 weeks of starting treatment, though measurable weight loss typically becomes apparent after 6-8 weeks. Maximum results are usually achieved around 12-16 weeks as doses reach therapeutic levels. Continued weight loss may persist through 6-12 months of consistent treatment with proper nutrition and lifestyle support.

What is the cost difference between semaglutide and tirzepatide at PlexusDx?

Compounded semaglutide injection starts at $149/month while tirzepatide injection starts at $249/month. Both medications maintain flat pricing regardless of dose level, meaning your cost remains predictable as your healthcare provider adjusts your dose upward. Oral formulations cost $249/month for semaglutide and $279/month for tirzepatide, with no insurance required and HSA/FSA eligibility available.

Are there side effects I should know about?

Both medications commonly cause mild to moderate gastrointestinal effects including nausea, vomiting, and constipation, typically most pronounced during dose escalation and diminishing over time. Tirzepatide may cause slightly more GI side effects due to its dual mechanism, though most patients report tolerability improves after 2-3 weeks. Serious side effects are rare but include pancreatitis and severe allergic reactions; patients with personal or family history of medullary thyroid cancer should not use these medications.

Can the Precision Peptide Genetic Test help me choose between semaglutide and tirzepatide?

Yes—PlexusDx's genetic test examines 14 metabolic pathways including GLP1R, GIPR, FTO, and MC4R variants that influence how your body responds to GLP-1 and GIP pathway activation. The test generates 150+ personalized genetic insights that can predict whether you'll respond optimally to semaglutide's single-pathway mechanism or tirzepatide's dual-pathway approach. The test costs $99 after your first month of treatment and provides data-driven guidance for optimizing your weight loss therapy.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves